Skip to main content
SpringerLink
Log in

Delayed periportal enhancement: a characteristic finding on contrast ultrasound in idiopathic portal hypertension

  • Original Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Purpose

Differentiation of idiopathic portal hypertension (IPH) from cirrhosis is not always easy because of their similar clinical features. This prospective study aimed to use contrast-enhanced ultrasound (US) in studying dynamic behavior of microbubble for characteristic enhancement features in IPH.

Methods

The study had 101 subjects: 8 IPH, 47 cirrhosis, and 36 controls, and additional ten cirrhosis for data validation. Contrast-enhanced US with perflubutane microbubble agent was performed in the early-phase (0–60 s) to compare hepatic enhancements among the three groups.

Results

Onset time of enhancement in the hepatic artery was not different among the groups, but that in the portal vein was longer in cirrhosis (19.9 ± 5.2 s; p = 0.0014) and IPH (22.9 ± 5.0 s; p = 0.0007) than in controls (16.6 ± 3.4 s). As for parenchymal enhancement, all controls showed homogeneous enhancement, while all IPH showed delayed periportal enhancement. Cirrhosis had three patterns: 14 with homogeneous enhancement, 28 with diffuse heterogeneous enhancement, and 5 with IPH-like delayed periportal enhancement. Homogeneous enhancement was more frequent in controls than in cirrhosis/IPH (p < 0.0001), and delayed periportal enhancement was more frequent in IPH than in control/cirrhosis (p < 0.0001). The duration of intensity difference between hypoenhancement/delayed enhancement area and surrounding parenchyma which exceeded the half of the mean value of the maximum intensity difference (8.75 dB for IPH, 6.95 dB for cirrhosis) was longer in IPH (15.6 ± 6.9 s) than cirrhosis (10.2 ± 5.3 s; p = 0.0119). The data in cirrhosis were validated in the additional ten subjects.

Conclusions

Delayed periportal enhancement on the sonograms based on perflubutane microbubble agent may be a characteristic of IPH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008;371:838–851

    Article  PubMed  CAS  Google Scholar 

  2. Hillaire S, Valla DC, Lebrec D. Non cirrhotic portal hypertension. Clin Liver Dis 1997;1:1223–1240

    Article  Google Scholar 

  3. Okuda K. Non-cirrhotic portal hypertension versus idiopathic portal hypertension. J Gastroenterol Hepatol 2002;17:S204–S213

    Article  PubMed  Google Scholar 

  4. Ohnishi K, Saito M, Sato S, et al. Portal hemodynamics in idiopathic portal hypertension (Banti’s syndrome). Comparison with chronic persistent hepatitis and normal subjects. Gastroenterology 1987;92:751–758

    PubMed  CAS  Google Scholar 

  5. Dhiman RK, Chawla Y, Vasishta RK, et al. Non-cirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and a review of the literature. J Gastroenterol Hepatol 2002;17:6–16

    Article  PubMed  Google Scholar 

  6. Hillaire S, Bonte E, Denninger M-H, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut 2002;51:275–280

    Article  PubMed  CAS  Google Scholar 

  7. Futagawa S, Fukazawa M, Horisawa M, et al. Portographic liver changes in idiopathic noncirrhotic portal hypertension. AJR Am J Roentgenol 1980;134:917–923

    PubMed  CAS  Google Scholar 

  8. Sarin SK, Kapoor D. Non-cirrhotic portal fibrosis: current concepts and management. J Gastroenterol Hepatol 2002;17:526–534

    Article  PubMed  CAS  Google Scholar 

  9. Waguri N, Suda T, Kamura T, Aoyagi Y. Heterogeneous hepatic enhancement on CT angiography in idiopathic portal hypertension. Liver 2002;22:276–280

    Article  PubMed  Google Scholar 

  10. Marelli C. Preliminary experience with NC100100, a new ultrasound contrast agent for intravenous injection. Eur Radiol 1999;9:S343–S346

    Article  PubMed  Google Scholar 

  11. Burns PN, Wilson SR, Simpson DH. Pulse inversion imaging of liver blood flow: improved method for characterizing focal masses with microbubble contrast. Invest Radiol 2000;35:58–71

    Article  PubMed  CAS  Google Scholar 

  12. Lencioni R, Piscaglia F, Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol 2008;48:848–857

    Article  PubMed  Google Scholar 

  13. Maruyama H, Takahashi M, Ishibashi H, et al. Ultrasound-guided treatments under low acoustic power contrast harmonic imaging for hepatocellular carcinomas undetected by B-mode ultrasonography. Liver Int 2009;29:708–714

    Article  PubMed  Google Scholar 

  14. Ishibashi H, Maruyama H, Takahashi M, Fujiwara K, Imazeki F, Yokosuka O. Assessment of hepatic fibrosis by analysis of the dynamic behavior of microbubbles during contrast ultrasonography. Liver Int 2010;30:1355–1363

    Article  PubMed  Google Scholar 

  15. The Japan Society for Portal Hypertension. The General Rules for Study of Portal Hypertension. 2nd edn. 2004;91–92

  16. Tsuneyama K, Ohba K, Zen Y, et al. A comparative histological and morphometric study of vascular changes in idiopathic portal hypertension and alcohol fibrosis/cirrhosis. Histopathology 2003;43:55–61

    Article  PubMed  CAS  Google Scholar 

  17. Nelson TR, Pretorius DH. Three-dimensional ultrasound imaging. Ultrasound Med Biol 1998;24:1243–1270

    Article  PubMed  CAS  Google Scholar 

  18. Maruyama H, Ishibashi H, Takahashi M, Imazeki F, Yokosuka O. Effect of signal intensity from the accumulated microbubbles in the liver for differentiation of idiopathic portal hypertension from liver cirrhosis. Radiology 2009;252:587–594

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Clinical Oncology, Chiba University Graduate School of Medicine, 1-8-1, Inohana, Chuou-ku, Chiba, 260-8670, Japan

    Hitoshi Maruyama, Taro Shimada, Hiroyuki Ishibashi, Masanori Takahashi, Hidehiro Kamesaki & Osamu Yokosuka

Authors
  1. Hitoshi Maruyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taro Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroyuki Ishibashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masanori Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hidehiro Kamesaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Osamu Yokosuka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hitoshi Maruyama.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (AVI 7912 kb)

Supplementary material 2 (AVI 8442 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maruyama, H., Shimada, T., Ishibashi, H. et al. Delayed periportal enhancement: a characteristic finding on contrast ultrasound in idiopathic portal hypertension. Hepatol Int 6, 511–519 (2012). https://doi.org/10.1007/s12072-011-9285-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-011-9285-8

Keywords

Search

Navigation